The multi-receptor inhibitor axitinib reverses tumor-induced immunosuppression and potentiates treatment with immune-modulatory antibodies in preclinical murine models

Cancer Immunology, Immunotherapy : CII
Heinz LäubliAlfred Zippelius

Abstract

Cancer immunotherapies have significantly improved the prognosis of cancer patients. Despite the clinical success of targeting inhibitory checkpoint receptors, including PD-1 and/or CTLA-4 on T cells, only a minority of patients derive benefit from these therapies. New strategies to improve cancer immunotherapy are therefore needed. Combination therapy of checkpoint inhibitors with targeted agents has promisingly shown to increase the efficacy of immunotherapy. Here, we analyzed the immunomodulatory effects of the multi-receptor tyrosine kinase inhibitor axitinib and its efficacy in combination with immunotherapies. In different syngeneic murine tumor models, axitinib showed therapeutic efficacy that was not only mediated by VEGF-VEGFR inhibition, but also through the induction of anti-cancer immunity. Mechanistically, a significant reduction of immune-suppressive cells, including a decrease of tumor-promoting mast cells and tumor-associated macrophages was observed upon axitinib treatment. Inhibition of mast cells by axitinib as well as their experimental depletion led to reduced tumor growth. Of note, treatment with axitinib led to an improved T cell response, while the latter was pivotal for the therapeutic efficacy. Combina...Continue Reading

References

Nov 18, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Dana D Hu-LoweSteve L Bender
Jun 18, 2011·Drugs in R&D·Bernard Escudier, Martin Gore
Jan 18, 2012·The Journal of Immunology : Official Journal of the American Association of Immunologists·Minoru SawaguchiMasato Kubo
Apr 25, 2012·Cancer Immunology, Immunotherapy : CII·Dyana K Dalton, Randolph J Noelle
Jan 22, 2013·Immunity·Virna Cortez-RetamozoMikael J Pittet
Apr 30, 2013·The Journal of Biological Chemistry·Franziska StehleBarbara Seliger
Jun 14, 2013·Oncoimmunology·Virna Cortez-RetamozoMikael J Pittet
Apr 5, 2014·Molecular Immunology·Sharon A Oldford, Jean S Marshall
Jan 21, 2015·The Journal of Experimental Medicine·Thibault VoronMagali Terme
Apr 11, 2015·Cancer Cell·Suzanne L TopalianDrew M Pardoll
Jun 2, 2015·The New England Journal of Medicine·James LarkinJedd D Wolchok
Jul 15, 2015·The Journal of Clinical Investigation·Douglas Marvel, Dmitry I Gabrilovich
Jul 25, 2015·Nature Reviews. Cancer·Ignacio MeleroJohn Haanen
Jul 25, 2015·Nature Reviews. Immunology·E John Wherry, Makoto Kurachi
Jan 20, 2017·Nature·Daniel S Chen, Ira Mellman
Jan 26, 2017·The New England Journal of Medicine·Toni K Choueiri, Robert J Motzer
Apr 28, 2017·Frontiers in Immunology·Gilda VarricchiFrancescopaolo Granata

❮ Previous
Next ❯

Citations

Nov 21, 2018·Journal of Cellular and Molecular Medicine·Yin-Siew LaiKo-Tung Chang
Nov 28, 2018·International Journal of Cancer. Journal International Du Cancer·Kamal PandeyYong Wha Moon
Jan 10, 2019·International Journal of Molecular Sciences·David J Zahavi, Louis M Weiner
Jul 18, 2018·Frontiers in Oncology·Iratxe Zuazo-Gaztelu, Oriol Casanovas
May 19, 2018·Frontiers in Immunology·Ju YangBaorui Liu
Jan 1, 2020·Proceedings of the National Academy of Sciences of the United States of America·Abhishek S KashyapAlfred Zippelius
Nov 19, 2020·Nanoscale Horizons : the Home for Rapid Reports of Exceptional Significance in Nanoscience and Nanotechnolgy·Yaxin ZhouYuxia Luan
Jan 18, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·David H AggenBrian I Rini
Feb 13, 2021·Expert Opinion on Biological Therapy·Viktoria StühlerJens Bedke
Apr 16, 2021·Frontiers in Immunology·Morgane BourhisMagali Terme
May 15, 2019·Journal of Medicinal Chemistry·Junting ZhouHaopeng Sun
Aug 25, 2021·Aktuelle Urologie·Isabel Virchow, Viktor Grünwald

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

Cell Signaling by Tyrosine Kinases

Receptor tyrosine kinases (RTKs) are the high-affinity cell surface receptors for many polypeptide growth factors, cytokines, and hormones. RTKs have been shown not only to be key regulators of normal cellular processes but also to have a critical role in the development and progression of many types of cancer. Discover the latest research on cell signaling and RTK here.

© 2022 Meta ULC. All rights reserved